Rheumatoid Arthritis Market Size, Share, Analysis, Top Leaders, Value & Volume, Technological Advancement and Macro Economical

Global Rheumatoid arthritis market Information, by drug type (Nonsteroidal anti-inflammatory drug type (NSAID), Steroids, Biologic agents) by diagnosis (C-Reactive Protein (CRP) Test, CCP, ESR test) by treatment (Synovectomy, Tendon repair, Joint fusion) - Forecast to 2022

Rheumatoid arthritis Market Highlights

The market for rheumatoid arthritis could project an excellent growth during the forecast period (2016-2022), says Market Research Future (MRFR).

Market Boosters and Top Barriers

The most fundamental factors leading to market growth are the availability of novel biologics, surge in potential clinical pipeline candidates, and expanding aging population. Considering the increasing availability and awareness of effective and safe drugs, the rheumatoid arthritis drugs market could expect a superlative run during the appraisal period.

Request Free Sample @https://www.marketresearchfuture.com/sample_request/1658

Rising prevalence of the disease, well-defined regulatory guidelines, and presence of biologics & biosimilars will have a lucrative effect on the market. The Arthritis Foundation says that close to 64% of the population in the United States (U.S.) aged 65 or above is prone to arthritis. As a result, mounting awareness about disease remittance therapies coupled with the rise in healthcare expenditure in developed areas, could accelerate market revenue in the subsequent years.

Existing treatment for rheumatoid arthritis is generic pharmaceuticals including corticosteroids and NSAIDs combined with novel biologics such as IL-6 antagonists and JAK inhibitors. These are widely used in economically stable countries owing to their high effectiveness and safety. Latest product launches like Adalimumab biosimilars and Infliximab could favor the market in the long run. Also, AbbVie’s Upadacitinib and Eli Lilly’s Olumiant are expected to bring down the chances of disease remittance.

Rheumatoid arthritis Market Segmentation

The worldwide market for rheumatoid arthritis has been segmented on the basis of diagnosis, drug type, and treatment.

With respect to the diagnosis, the market is considered for C-Reactive Protein (CRP) Test, cyclic citrullinated peptide (CCP), and erythrocyte sedimentation rate (ESR) test.

Depending on the drug types, the market includes biologic agents, Disease-modifying anti-rheumatic drug type (DMARDs), Non-steroidal anti-inflammatory drug type (NSAID), and steroids.

The treatment-based segments are joint fusion, synovectomy, and tendon repair. With increasing reimbursement policy changes along with new product entrants, the market for joint fusion has taken a leap in recent years.

Rheumatoid arthritis Market Regional Analysis

The geographical distribution of the global rheumatoid arthritis market covers Europe, Asia Pacific, Middle East & Africa, and North America.

North America is the most profitable market for rheumatoid arthritis backed by the presence of well-developed medical facilities and sophisticated healthcare infrastructure. The United States (US) and Canada are the leading markets in the region.

After North America, Europe is the most lucrative market as a result of a considerable number of advanced medical facilities. A significant portion of the revenue comes from Germany, France, Spain, the United Kingdom (UK), and Italy. The region notes the rigorous expansion of the geriatric population, which accelerates the demand for rheumatoid arthritis treatment.

Asia Pacific is said to be growing at the fastest rate with the vast improvement in terms of healthcare scenario. There has been a surge in medical facilities backed by rising urbanization and consistent technological advancement. These factors have also resulted in a favorable environment for medical tourism, an industry that has been rapidly expanding in the region. The large portion of the regional market is controlled by China, Australia, Japan, South Korea, and India, among others.

Middle East and Africa remains the smallest market for rheumatoid arthritis, in response to the lack of education and sluggish infrastructure development. The abysmal growth of the healthcare sector and political instability also have a big hand in the poor market performance. However, Saudi Arabia, Egypt, the United Arab Emirates (UAE), and South Africa are some of the countries that show promise and could expect somewhat decent growth in the near future.

Rheumatoid arthritis Market Prominent Vendors

Prominent vendors within the worldwide rheumatoid arthritis market are AstraZeneca (UK), Vertex Pharmaceuticals Incorporated (USA), Eli Lilly and Company (USA), Pfizer Inc (USA), Bristol-Myers Squibb Company (USA), Sanofi (France), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), to name a few.

OBTAIN RESEARCH REPORT DETAILS WITH TOC @https://www.marketresearchfuture.com/reports/rheumatoid-arthritis-market-1658

Industry Update

July 2019

GlaxoSmithKline (GSK) recently started with a Phase III program for the rheumatoid arthritis candidate which has led to a substantial payment to MorphoSys of USD 24.9 million. The program will evaluate the safety as well as efficacy of two doses of otilimab, which will involve three vital trials that will compare it with two marketed arthritis therapies.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Info:
Name: Reshu
Email: Send Email
Organization: Market Research Future
Address: WantStats Research and Media Pvt. Ltd. Office No. 528, Amanora Chambers
Phone: 6468459312
Website: https://www.marketresearchfuture.com/

Release ID: 88898183